Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: Quality of life and 6-years'-follow-up results from a randomised phase III trial

Lung Cancer

Volumn 53, Issue 1, 2006, Pages 67-75

  Reck, Martin ^a   von Pawel, Joachim ^b   Macha, Hans Nicholas ^c   Kaukel, Eckhard ^d   Deppermann, Karl Matthias ^e   Bonnet, Reiner ^f   Ulm, Kurt ^g   Hessler, Sybill ^h   Gatzemeier, Ulrich ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^c Hospital of Lung Diseases Hemer   (Germany)

^d Asklepios Klinik Harburg   (Germany)

^e Ruppiner Kliniken   (Germany)

^f Central Hospital Bad Berka   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

5 year survival; Chemotherapy; Lung cancer; Paclitaxel; Quality of life; SCLC

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOFOS; PACLITAXEL; VINCRISTINE;

ADULT; AGED; APPETITE DISORDER; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SLEEP DISORDER; SURVIVAL TIME; TREATMENT DURATION; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL RATE; VINCRISTINE;

EID: 33744799708     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.04.001     Document Type: Article

References (35)

1. Kurup A., and Hanna N.H. Treatment of small cell lung cancer. Crit Rev Oncol Hematol 52 (2004) 117-126
2. Stupp R., Monnerat C., Turrisi III A.T., Perry M.C., Leyvraz S., et al. Small cell lung cancer: state of the art and future perspectives. Lung Cancer 45 (2004) 105-117
3. Chute J.P., Chen T., Feigal E., Simon R., and Johnson B.E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 17 (1999) 1794-1801
4. Roth B.J., Johnson D.H., Einhorn L.H., Schacter L.P., Cherng N.C., Cohen H.J., et al., A phase III trial of the Southeastern Cancer Study Group. Randomised study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer. J Clin Oncol 10 (1992) 282-291
5. Fukuoka M., Furuse K., Saijo N., Nishiwaki Y., Ikegami H., Tamura T., et al. Randomised trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these two regimens in small-cell lung cancer. J Natl Cancer Inst 83 (1991) 855-861
6. Sundstrom S., Bremnes R.M., Kaasa S., Aasebo U., Hatlevoll R., Dahle R., et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20 (2002) 4665-4672
7. Skarlos D., Samantas E., Kosmidis P., Fountzilas G., Angelidou M., Palamidas P., et al., A Hellenic Co-operative Oncology Group study. Randomised comparison of etoposid-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. Ann Oncol 5 (1994) 601-607
8. Fokkema E., Groen H.J.M., Bauer J., Uges D.R., Weil C., and Smith I.E. Phase II study of JM216 as first line treatment in patients with small-cell lung cancer. J Clin Oncol 17 (1999) 3822-3827
9. Hainsworth J.D., Levitan N., Wampler G.L., Belani C.P., Seyedsadr M.S., Randolph J., et al. Phase II randomised study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer. J Clin Oncol 13 (1995) 1436-1442
10. Loehrer Sr. P.J., Ansari R., Gonon R., Monaco F., Fisher W., Sandler A., et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer. J Clin Oncol 13 (1995) 2594-2599
11. Schiller J.H., Adak S., Cella D., DeVore III R.F., Johnson D.H., and E7593-a phase III trial of the Eastern Cooperative Oncology Group. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer. J Clin Oncol 19 (2001) 2114-2122
12. Pujol J.L., Daurès J.P., Rivière A., Quoix E., Westell V., Quantin X., et al. Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in the treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 93 (2001) 300-308
13. Ettinger D.S., Finkelstein D.M., Sarma R.P., Johnson D.H., and An Eastern Cooperative Oncology Group study. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer. J Clin Oncol 13 (1995) 1430-1435
14. Kelly K., Lovato L., Bunn Jr. P.A., Livingston R.B., Zangmeister J., Taylor S.A., et al., A phase II trial of the Southwest Oncology Group. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer. Clin Cancer Res 7 (2001) 2325-2329
15. Mavroudis D., Papadakis E., Veslemes M., Tsiafaki X., Stavrakakis J., Kourossis C., et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 12 (2001) 463-470
16. Niell H.B., Herndon II J.E., Miller A.A., Watson D.M., Sandler A.B., Kelly K., et al. Randomised phase III Intergroup Trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive stage small-cell lung cancer: Cancer and Leucemia Group B Trial 9732. J Clin Oncol 23 (2005) 3752-3759
17. Ettinger DS, Berkey BA, Abrams RA, Fontanesi J, Machtay M, Duncan PJ, et al., Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol 23, 10.1200/JCO.2005.00.414
18. Gatzemeier U., Hossfeld D.K., Neuhauss R., Reck M., Achterrath W., and Lenaz L. Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer. J Clin Oncol 10 (1992) 818-823
19. Steward W.P., von Pawel J., Gatzemeier U., Woll P., Thatcher N., Koschel G., et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 16 (1998) 642-650
20. Hainsworth J.D., Stroup S.L., and Greco F.A. Paclitaxel, carboplatin and extended schedule etoposide in the treatment of small-cell lung carcinoma. Cancer 77 (1996) 2458-2463
21. Reck M., von Pawel J., Macha H.N., et al. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 95 (2003) 1118-1127
22. Pocock S.J. Clinical trials: a practical approach (1983), John Wiley & Sons, New York, NY
23. World Medical Association Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-6.
24. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7 (1989) 1748-1756
25. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
26. Peto R., and Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A135 (1972) 185-198
27. Cox D.R. Regression models and life tables. J R Stat Soc B34 (1972) 187-220
28. Aaronson N.K., Ahmedzai S., Gergman B., Bullinger M., Cull A., Duez N.J., et al. The European organization for research and treatment of cancer QLQ-30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
29. Lipsitz S.R., Fitzmaurice G.M., Orav E.J., and Laird N.M. Performance of generalized estimating equations in practical situations. Biometrics 50 (1994) 270-278
30. Lipsitz S.R., and Fitzmaurice G.M. Estimating equations for measures of association between repeated binary responses. Biometrics 52 (1996) 903-912
31. Norman G., Sloan J., and Wyrwich K. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41 (2003) 582-592
32. Laskin J., Sandler A., and Johnson D.H. An advance in small-cell lung cancer-more or less. J Natl Canc Inst 95 (2003) 1099-1101
33. Plunkett T.A., Chrystal K.F., and Harper P.G. Quality of life and the treatment of Advanced Lung Cancer. Clin Lung Cancer 5 (2003) 28-32
34. Birch R., Greco F.A., Hainsworth J.D., Schnell F., Waller J., Pettis C., et al. Preliminary results of a randomised study comparing etoposide and carboplatin (EP) with or without paclitaxel (T) in newly diagnosed small cell lung cancer. Proc ASCO 19 (2000) 1918 [abstract]
35. Greco F.A., Thompson D.S., Morrissey L.H., Erland J.B., Burris III H.A., Spigel D.R., et al. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial. Oncologist 10 (2005) 728-733